Bimekizumab Development Delayed by FDA

Save

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Read Article

Bimekizumab's Favorable Safety Profile in Psoriasis A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis.https://t.co/84zS8VET6B https://t.co/aLvLmmTc93

RNL 2022: Psoriatic Arthritis Advances

Save

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.

This webinar presented exerpts from these lectures along with audience Q & A

Read Article

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Save

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article

TNR - Controversies in PsA

Save

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.

The PsA Expert panelists included:

Read Article

ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ

Now Available: TNR - Psoriatic Arthritis Journal Club

Save

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article

Male vs. Female Responders (4.15.2022)

Save

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitorhttps://t.co/CfAjvc9XWg https://t.co/RaD5qqPM3a

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

Save

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article

2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv

ICYMI: Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/t5wrmE3nbK #PsA #PsAlways https://t.co/MQjgktOZWR

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Save

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

Read Article

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Save

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article

Ask Cush Anything! Have a rheumatology question or case for Dr. Cush? Submit it here and we may feature it on an upcoming podcast. https://t.co/KgPIeScthr https://t.co/nk4re9mlcH

"Remember bony growth is a feature of the PsA joint and one potential way in which IL17s may target the disease." Dr. B. Kirkham discusses potential synergistic activity of IL17A and TNFi in the SpA joint. #RNL2022 @RheumNow https://t.co/L9uZqoen2w

IL-17i - Good Long term safety profile and low malignancy risk Best efficacy for nail psoriasis @RheumNow #RNL2022 https://t.co/8T7wAGJChF